Report Date: Thursday, August 6, 2026 (after market close) | Call: Friday, August 7, 8:00 a.m. ET
Aflac shares have had a strong run into this print, trading around $125-126, near 52-week highs after climbing from roughly $108 in early January. The stock's momentum has been driven by consistent capital returns, resilient Japan profitability, and steady U.S. group-business growth, but it also means expectations — and the valuation bar — are elevated heading into tomorrow's release.
Consensus expectations: - Adjusted EPS of $1.77, roughly flat to down slightly versus $1.78 a year ago, on revenue of about $4.2 billion, which would represent a 7.7% year-over-year decline, largely a function of currency and reinsurance mechanics rather than underlying deterioration. - For full-year 2026, the consensus sits at EPS of ~$7.06-7.07, implying a ~5.6%-5.7% decline from 2025's record $7.49, with full-year revenue estimated around $16.8 billion, down about 9.1%. - By segment, consensus calls for Aflac Japan net earned premiums down 11.4% year-over-year (currency- and reinsurance-driven) while Aflac U.S. premiums grow ~2.2%; net investment income is expected down about 15.1%, and the U.S. benefit ratio is expected to tick up to 49.2% from 47.3% a year ago. - Aflac has a mixed beat/miss record recently, having topped estimates in two of the last four quarters and missed in the other two.
Analyst sentiment is notably split going in: Barclays reiterated an "underweight" rating in early July with a $98-99 price target, while Evercore ISI raised its target to $115 (from $109) and BofA raised its target to $137 (from $126); Mizuho remains at "sell." That dispersion reflects a real debate about whether Aflac's premium growth inflection in Japan is finally arriving or whether currency and structural lapse trends will keep capping upside.
Aflac's first quarter was a clean beat-and-raise-the-bar type of print. Highlights investors will be comparing Q2 against:
Management reaffirmed full-year 2026 guidance ranges set at Q4: Japan benefit ratio 60%-63%, expense ratio 20%-23%, pretax margin 33%-36%; U.S. net earned premium growth at the low end of 3%-6%, benefit ratio 48%-52%, expense ratio 36%-39%, pretax margin 17%-20%.
1. Yen translation headwind will bite harder than in Q1. The yen/dollar comparison gets tougher this quarter. Q2 2025's average rate was 144.60 yen/dollar (a period of relative yen strength), whereas the yen has weakened meaningfully over the past year (down roughly 7% over the trailing 12 months per recent FX data, trading in the upper-150s to low-160s heading into the print). A materially weaker yen versus last year's Q2 comp will suppress reported-dollar Japan premiums, investment income, and earnings even if underlying yen-denominated trends are healthy — this is largely why consensus models an 11.4% decline in Japan's dollar-denominated net earned premiums.
2. Is the Japan sales-to-earned-premium inflection actually showing up? This is the single biggest strategic question for the stock. Despite Japan sales growth running above 20% for multiple quarters (driven by Anshin Palette, Miraito, and Tsumitasu), underlying earned premium has stayed negative (roughly -1% to -2%). On the Q1 call, CFO Max Broden quantified the bar precisely: Aflac needs roughly ¥90 billion of annual sales to get to flat in-force premium, and CEO Dan Amos said his target for 2026 sales is "closer to JPY 80 billion," versus ¥74 billion in 2025. Watch Q2 Japan sales growth and management commentary on trajectory toward that goal — a Q2 slowdown from Q1's 25.5% pace (given tougher comps and new-product cannibalization dynamics flagged for cancer product Miraito) would raise questions about durability.
3. U.S. benefit ratio: was Q1's favorability sustainable? Aflac U.S. beat its own full-year benefit-ratio guidance range in Q1 (47.2% actual vs. 48%-52% full-year guide), driven partly by favorable group disability experience that management explicitly flagged as "quite volatile from quarter-to-quarter." Consensus already assumes some normalization, modeling a 49.2% U.S. benefit ratio for Q2 versus 47.3% a year ago. A ratio landing meaningfully above plan would be a negative surprise; continued favorability would support the bull case that underwriting discipline is structurally improving.
4. Capital deployment pace and the reinsurance optionality. Aflac entered the quarter with an ESR (Economic Solvency Ratio) around 227% (243% including the USP add-on) and combined U.S. RBC near 560%, alongside $2.4 billion of liquidity above its minimum threshold. Given ongoing dividend growth (44 consecutive years, extending the streak) and continued buybacks ($1.0 billion in Q1 alone), watch for the pace of repurchases in Q2 and any incremental color on scaling the new external reinsurance strategy in Japan, which management described as something that "could be material to us over time" and potentially accretive.
5. Corporate & Other segment — guided to turn slightly negative. Management explicitly guided this segment to run "slightly negative" in Q2 given short-term rate levels, ongoing ~8% annual runoff decay in closed reinsurance blocks, and higher interest expense — a modest known headwind to consolidated results that shouldn't surprise if it materializes as flagged.
6. Regulatory/company-specific tail risks. On the Q1 call, management pushed back on suggestions of broader state-regulator pressure on U.S. product rates, with U.S. President Virgil Miller saying the company is "seeing no material impacts at all" beyond an isolated, previously reported situation. Investors should listen for any update. Separately, Aflac's own disclosures continue to flag "uncertainty regarding the impact of the incident involving unauthorized access to the Company's network in June 2025" as an ongoing risk factor to monitor.
Heading into Thursday's print, the underlying business narrative is intact: Japan sales momentum from new products (Anshin Palette, Miraito, Tsumitasu) remains strong, U.S. group lines (dental/vision, life & disability) are growing double digits even as the legacy agent-driven block stays flat-to-down, and capital returns remain robust. The main swing factors for Q2 are (1) a tougher yen comp that will mechanically depress reported dollar growth, (2) whether U.S. underwriting favorability persists or normalizes toward the guided range, and (3) incremental disclosure on the Japan external-reinsurance growth lever. With the stock near highs and analyst price targets split roughly $98 to $137, the reaction is likely to hinge less on the headline EPS number (consensus $1.77, essentially in line with last year) and more on segment-level trends — particularly any fresh data point on Japan's earned-premium inflection and U.S. benefit-ratio durability.